Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein of SARS-CoV-2 (Omicron JN.1) (S protein)
- Target
- S protein
- Molecular classification
- Viral protein, Glycoprotein, Fusion protein
01
Overview
The spike glycoprotein (S protein) of the SARS-CoV-2 Omicron JN.1 variant is a trimeric, class I fusion protein on the viral surface. It mediates viral entry into host cells by binding to ACE2 and facilitating membrane fusion. JN.1 contains numerous mutations in the spike gene that enhance transmissibility and immune escape. It is the main target for neutralizing antibodies elicited by infection or vaccination.
- Other names
- Spike protein (Omicron JN.1)SARS-CoV-2 Spike glycoprotein (JN.1)S protein (JN.1 variant)
02
Mechanism of action
Neutralizing antibodies bind to the spike protein, preventing ACE2 binding and/or membrane fusion. Vaccines induce an antibody response targeting the spike protein.
03
Biological functions
Host cell attachmentMembrane fusionViral entryReceptor binding (ACE2)Antigenic target
04
Disease associations
InfectionCOVID-19Viral pathogenesisImmune evasion
05
Safety considerations
Antibody-dependent enhancement (ADE)Immune escape due to mutationsPotential for autoimmune reactions (theoretical)
06
Interacting drugs
Neutralizing antibodies
1 more in the full profile.
07
Biomarkers
Spike protein levels (viral load)Antibody titers against spike protein
Beyond the preview
Go deeper on Spike Glycoprotein of SARS-CoV-2 (Omicron JN.1) (S protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein of SARS-CoV-2 (Omicron JN.1) (S protein).